Wells Fargo reiterated coverage on Emergent BioSolutions with a new price target

3/10/22 7:10:05 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Wells Fargo reiterated coverage of Emergent BioSolutions with a rating of Equal-Weight and set a new price target of $40.00 from $37.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EBS

Date	Price Target	Rating	Analyst
12/30/2024	$15.00	Buy	H.C. Wainwright
8/22/2024	$16.00	Buy	Rodman & Renshaw
3/7/2024	$5.00	Hold → Buy	The Benchmark Company
11/20/2023		Underweight	JP Morgan
8/29/2023		Buy → Hold	The Benchmark Company
4/10/2023	$22.00	Hold → Buy	The Benchmark Company
3/17/2023	$23.00 → $9.00	Neutral → Underweight	JP Morgan
11/10/2022		Buy → Hold	The Benchmark Company